EPS Creative Health Technology Group Limited

Research EPS Creative Health Technology Group Limited (3860.HK) on Bullrun: market cap HKD 349.46M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is HKD 349.46M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2026HKD 457.65M-HKD 13.85MHKD 25.12M16.4%n/aHKD 126.49MHKD 4.45MHKD 105.91M
FY2025HKD 544.52MHKD 38.59M-HKD 23.63M17.4%0.07HKD 135.69MHKD 6.68MHKD 120.68M
FY2024HKD 644.62M-HKD 22.07M-HKD 33.60M15.4%-0.04HKD 115.54MHKD 11.45MHKD 65.36M
FY2023HKD 452.91M-HKD 45.74M-HKD 40.52M15.0%-0.09HKD 131.47MHKD 2.71MHKD 87.64M
FY2022n/an/an/an/a-0.05n/an/an/a

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-10-18HKD 349.46Mn/an/a0.01

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0.01 HKD.

YearDividends/share
FY20250.01 HKD

About EPS Creative Health Technology Group Limited

EPS Creative Health Technology Group Limited, an investment holding company, operates as an apparel supply chain management service provider in Hong Kong, Mainland China, Japan, the United States, Europe, and internationally. The company operates through Garment Business; Healthcare Products Business; and IRO with CRO and In-House R&D Business segments. It offers knitwear products, such as women's, men's, and kid's wear products;

Related stock research

Other Consumer Cyclical stocks

Frequently asked questions

What is EPS Creative Health Technology Group Limited's market cap?

EPS Creative Health Technology Group Limited's market capitalization is HKD 349.46M.

What does EPS Creative Health Technology Group Limited do?

EPS Creative Health Technology Group Limited, an investment holding company, operates as an apparel supply chain management service provider in Hong Kong, Mainland China, Japan, the United States, Europe, and internationally. The company operates through Garment Business; Healthcare Products Business; and IRO with CRO and In-House R&D Business segments.